Die Zukunft der Nuklearkardiologie

Zusammenfassung

Die Nuklearkardiologie ist im Wandel. Die Zeiten, in denen man als Nuklearkardiologe ähnlich einem reinen Dienstleister Myokardperfusionsszintigrafien durchführte und befundete, haben sich zugunsten einer größeren Vielseitigkeit geändert. Es tun sich neue, vielversprechende Anwendungsfelder auf, die eine enge Kooperation mit den klinischen Partnern erfordern. Zu diesen Anwendungsfeldern gehören insbesondere Infektions- und Inflammationserkrankungen sowie die kardiale Amyloidose. Des Weiteren ist die künstliche Intelligenz auf dem Vormarsch. Wird der Nuklearmediziner dann noch gebraucht? Quo vadis, Nuklearkardiologie?

Abstract

Nuclear cardiology is changing. The times in which nuclear cardiologists, like pure service providers, performed and reported myocardial perfusion scintigraphy have changed towards a broader spectrum. New, promising fields of application are opening up that require close cooperation with clinical partners. These fields include in particular infectious and inflammatory diseases as well as cardiac amyloidosis. Artificial intelligence is also on the advance. Will the nuclear physician still be needed? Quo vadis, nuclear cardiology?

Schlüsselwörter

Perfusion - Amyloidose - Infektionsbildgebung - Inflammationsbildgebung - Kardio-Onkologie - künstliche Intelligenz

Keywords

perfusion - amyloidosis - infection imaging - inflammation imaging - cardio-oncology - artificial intelligence

Publikationsverlauf

Artikel online veröffentlicht:
28. Februar 2020

• Literatur

• 1 Blumgart HL, Yens OC. STUDIES ON THE VELOCITY OF BLOOD FLOW: I. The Method Utilized [Internet]. 1927 [cited 2019 Dec 9] Available from: https://www.jci.org/articles/view/100106/scanned-page/9
• 2 Patton DD. The Birth of Nuclear Medicine Instrumentation: Blumgart and Yens, 1925. J Nucl Med 2003; 44: 1362-1365
• 3 Carrea JR, Gleason G, Shaw J. et al. The direct diagnosis of myocardial infarction by photoscanning after administration of cesium-131. Am Heart J 1964; 68: 627-636
• 4 Lindner O, Burchert W, Buechel R. et al. Myocardial Perfusion SPECT 2018 in Germany: Results of the 8th Survey. Nuklearmedizin. 2019; 58: 425-433
• 5 Chen J, Einstein AJ, Fazel R. et al. Cumulative Exposure to Ionizing Radiation from Diagnostic and Therapeutic Cardiac Imaging Procedures: A Population-Based Analysis. J Am Coll Cardiol 2010; 56: 702-711
• 6 Knuuti J, Wijns W, Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal 2019; ehz425
• 7 Fihn SD, Blankenship JC, Alexander KP. et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014; 64: 1929-1949
• 8 Murthy VL, Bateman TM, Beanlands RS. et al. Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. J Nucl Med 2018; 59: 273-293
• 9 Gaemperli O, Bengel FM, Kaufmann PA. Cardiac hybrid imaging. Eur Heart J 2011; 32: 2100-2108
• 10 Sharir T, Ben-Haim S, Merzon K. et al. High-speed myocardial perfusion imaging initial clinical comparison with conventional dual detector anger camera imaging. JACC Cardiovasc Imaging 2008; 1: 156-163
• 11 Einstein AJ, Blankstein R, Andrews H. et al. Comparison of image quality, myocardial perfusion, and left ventricular function between standard imaging and single-injection ultra-low-dose imaging using a high-efficiency SPECT camera: the MILLISIEVERT study. J Nucl Med 2014; 55: 1430-1437
• 12 Agostini D, Roule V, Nganoa C. et al. First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera: head to head comparison with 15O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study. Eur J Nucl Med Mol Imaging 2018; 45: 1079-1090
• 13 Knuuti J, Bengel F, Bax JJ. et al. Risks and benefits of cardiac imaging: an analysis of risks related to imaging for coronary artery disease. Eur Heart J 2014; 35: 633-638
• 14 Lalani T, Chu VH, Park LP. et al. In-Hospital and 1-Year Mortality in Patients Undergoing Early Surgery for Prosthetic Valve Endocarditis. JAMA Intern Med 2013; 173: 1495-1504
• 15 Swart LE, Scholtens AM, Tanis W. et al. 18F-fluorodeoxyglucose positron emission/computed tomography and computed tomography angiography in prosthetic heart valve endocarditis: from guidelines to clinical practice. Eur Heart J 2018; 39: 3739-3749
• 16 Takemiya K, Ning X, Seo W. et al. Novel PET and Near Infrared Imaging Probes for the Specific Detection of Bacterial Infections Associated With Cardiac Devices. JACC Cardiovasc Imaging 2019; 12: 875-886
• 17 Habib G, Lancellotti P, Antunes MJ. et al. 2015 ESC Guidelines for the management of infective endocarditisThe Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36: 3075-3128
• 18 Hesse B, Lindhardt TB, Acampa W. et al. EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging 2008; 35: 851-885
• 19 Mahabadi AA, Rischpler C. Cardiovascular imaging in cardio-oncology. J Thorac Dis 2018; 10 (Suppl. 35) S4351-4366
• 20 Lindner T, Loktev A, Altmann A. et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med 2018; 59: 1415-1422
• 21 Totzeck M, Siebermair J, Rassaf T. et al. Cardiac fibroblast activation detected by positron emission tomography/computed tomography as a possible sign of cardiotoxicity. Eur Heart J. 2019;
• 22 Seferović PM, Polovina M, Bauersachs J. et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21: 553-576
• 23 Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J [Internet] 2018; 8: 44 [cited 2019 Nov 22] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966459/
• 24 Maurer MS, Schwartz JH, Gundapaneni B. et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine 2018; 379: 1007-1016
• 25 Benson MD, Waddington-Cruz M, Berk JL. et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med 2018; 379: 22-31
• 26 Minamisawa M, Claggett B, Adams D. et al. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study. JAMA Cardiol 2019; 4: 466-472
• 27 Solomon SD, Adams D, Kristen A. et al. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation 2019; 139: 431-443
• 28 Gillmore JD, Maurer MS, Falk RH. et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016; 133: 2404-2412
• 29 Antoni G, Lubberink M, Estrada S. et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2013; 54: 213-220
• 30 Dorbala S, Vangala D, Semer J. et al. Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014; 41: 1652-1662
• 31 Law WP, Wang WYS, Moore PT. et al. Cardiac Amyloid Imaging with 18F-Florbetaben PET: A Pilot Study. J Nucl Med 2016; 57: 1733-1739
• 32 Kim YJ, Ha S, Kim Y-I. Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis. J Nucl Cardiol 2018;
• 33 Betancur J, Rubeaux M, Fuchs TA. et al. Automatic Valve Plane Localization in Myocardial Perfusion SPECT/CT by Machine Learning: Anatomic and Clinical Validation. J Nucl Med 2017; 58: 961-967
• 34 Arsanjani R, Dey D, Khachatryan T. et al. Prediction of revascularization after myocardial perfusion SPECT by machine learning in a large population. J Nucl Cardiol 2015; 22: 877-884
• 35 Betancur J, Otaki Y, Motwani M. et al. Prognostic Value of Combined Clinical and Myocardial Perfusion Imaging Data Using Machine Learning. J Am Coll Cardiol Img 2018; 11: 1000-1009